It's certainly possible. We only need to about triple up from here to catch Compass. The sector is growing a lot faster than anyone could have anticipated. I do think a cool off is coming, because we can't escape the fact that clinical trials need to happen and actual drug approval and sales are still at least 2.5 years away for 18-MC. Likely to be several more rounds of stock offerings between now and then, also.
News 
Market Data 
Discover 
AI
